MA46565A - Oxystérols et leurs procédés d'utilisation - Google Patents

Oxystérols et leurs procédés d'utilisation

Info

Publication number
MA46565A
MA46565A MA046565A MA46565A MA46565A MA 46565 A MA46565 A MA 46565A MA 046565 A MA046565 A MA 046565A MA 46565 A MA46565 A MA 46565A MA 46565 A MA46565 A MA 46565A
Authority
MA
Morocco
Prior art keywords
oxysterols
methods
Prior art date
Application number
MA046565A
Other languages
English (en)
Inventor
Andrew Griffin
Boyd L Harrison
Daniel La
Botella Gabriel Martinez
Albert J Robichaud
Francesco G Salituro
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MA46565A publication Critical patent/MA46565A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
MA046565A 2016-10-18 2017-10-18 Oxystérols et leurs procédés d'utilisation MA46565A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662409756P 2016-10-18 2016-10-18
US201662409768P 2016-10-18 2016-10-18

Publications (1)

Publication Number Publication Date
MA46565A true MA46565A (fr) 2019-08-28

Family

ID=60263022

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046565A MA46565A (fr) 2016-10-18 2017-10-18 Oxystérols et leurs procédés d'utilisation

Country Status (14)

Country Link
US (4) US11111266B2 (fr)
EP (3) EP4616908A3 (fr)
JP (4) JP2019532079A (fr)
KR (3) KR20250054838A (fr)
CN (3) CN110072874B (fr)
AU (3) AU2017345399B2 (fr)
DK (1) DK4105223T3 (fr)
ES (2) ES2968140T3 (fr)
IL (3) IL320521A (fr)
MA (1) MA46565A (fr)
MX (2) MX2019004679A (fr)
RU (1) RU2019115112A (fr)
TW (3) TWI836485B (fr)
WO (1) WO2018075698A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150158903A1 (en) 2011-09-08 2015-06-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
LT2968369T (lt) 2013-03-13 2018-12-27 Sage Therapeutics, Inc. Neuroaktyvūs steroidai ir jų panaudojimo būdai
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
RS62220B1 (sr) 2015-07-06 2021-09-30 Sage Therapeutics Inc Oksisteroli i postupci njihovog korišćenja
MX376833B (es) 2015-07-06 2025-03-07 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
CN114272249A (zh) 2016-04-01 2022-04-05 萨奇治疗股份有限公司 氧甾醇及其使用方法
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2017292870B2 (en) 2016-07-07 2021-10-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3519422B1 (fr) 2016-09-30 2022-08-31 Sage Therapeutics, Inc. Oxystérols substitués en c7 et ces composés pour l'utilisation en tant que modulateurs nmda
KR20250054838A (ko) 2016-10-18 2025-04-23 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
ES2952106T3 (es) 2016-10-18 2023-10-27 Sage Therapeutics Inc Oxisteroles y procedimientos de utilización de los mismos
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN111560045A (zh) * 2020-06-23 2020-08-21 江苏佳尔科药业集团股份有限公司 一种以ba为原料合成石胆酸的方法
CN112375117A (zh) * 2020-11-14 2021-02-19 湖南科瑞生物制药股份有限公司 石胆酸及其中间体的制备方法
CN113651866B (zh) * 2021-08-02 2023-07-04 王涛 一种以21-羟基-20-甲基孕甾-4-烯-3-酮为原料合成胆固醇的新方法
EP4430056A1 (fr) * 2021-11-10 2024-09-18 Umecrine AB Stéroïdes 3?-hydroxy, 3?-éthyle pour la modulation du sous-type ?3 du récepteur gaba-a
EP4433475A4 (fr) 2021-11-15 2026-01-14 Hepaitech Beijing Biopharma Tech Co Ltd Composés polycycliques et leurs procédés
JP2025512885A (ja) 2022-03-30 2025-04-22 ドナルドソン カンパニー，インコーポレイティド 溶媒を再利用するためのシステム及び方法
US20250375459A1 (en) * 2022-07-01 2025-12-11 Intercept Pharmaceuticals, Inc. Methods for ameliorating cognitive impairment using bile acid derivatives
IL320996A (en) * 2022-11-21 2025-07-01 Sage Therapeutics Inc Negative NMDA modulator compounds and methods of using them
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
WO2025020191A1 (fr) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 Composé stéroïde, son procédé de préparation et son utilisation
WO2025250816A1 (fr) * 2024-05-29 2025-12-04 Sage Therapeutics, Inc. Agents pour administrer des composés modulant le récepteur nmda et leurs procédés d'utilisation

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259698A (en) 1938-05-07 1941-10-21 Rare Chemicals Inc Physiologically effective substance and process of preparing same
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (fr) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4269777A (en) 1979-05-21 1981-05-26 Wisconsin Alumni Research Foundation Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd ２４，２５−エポキシコレステロ−ル類の製造法
JPH03500049A (ja) 1987-08-25 1991-01-10 ジー、ケルビン・ダブリュー ストレス、不安および発作活性の緩和のための組成物および方法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
NZ282939A (en) 1994-02-14 1998-08-26 Cocensys Inc Androstanes and pregnanes for allosteric modulation of gaba receptors
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
WO1996016076A1 (fr) 1994-11-23 1996-05-30 Cocensys, Inc. Series de l'androstane et de la pregnane produisant une modulation allosterique du recepteur du gaba
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
KR19990022323A (ko) 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
RU2182909C2 (ru) 1995-06-23 2002-05-27 Ново Нордиск А/С Стероиды, способ регулирования мейоза
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
EP0840612A1 (fr) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition de l'activite des recepteurs du n-methyl-d-aspartate au moyen de derives de sulfate de pregnenolone
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
WO1997042215A1 (fr) 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Procede de preparation de 27-hydroxy cholesterol et de derives apparentes
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
WO1999058497A1 (fr) 1998-05-11 1999-11-18 Novo Nordisk A/S Guanidines et diaminonitroethenes substituees, preparation et applications
IL139241A0 (en) 1998-05-13 2001-11-25 Novo Nordisk As Meiosis regulating compounds
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
CN1187367C (zh) 1999-04-29 2005-02-02 欧洲凯尔特股份有限公司 具有麻醉剂活性的3α－羟基－3β－甲氧基甲基－21－杂环取代的类固醇
US6376530B1 (en) 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
DK1392713T3 (da) 2001-05-03 2008-02-18 Univ Chicago Lever-X-receptoragonister
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
EP1450816A4 (fr) 2001-11-08 2008-02-13 Univ Chicago Methode de traitement de troubles lies a un taux de cholesterol eleve
AU2002360489A1 (en) 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
CN102727501A (zh) 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
NZ547344A (en) 2002-03-27 2007-11-30 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
WO2004055201A2 (fr) 2002-12-13 2004-07-01 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) utilisee en tant que cible therapeutique pour le traitement de la maladie d'alzheimer
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
WO2006037016A2 (fr) 2004-09-27 2006-04-06 The Regents Of The University Of California Nouvelle therapie destinee au traitement de maladies cerebrales degeneratives chroniques et d'une lesion du systeme nerveux
US20070032464A1 (en) 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
AU2005302452B2 (en) 2004-11-01 2010-12-09 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
CA2643732C (fr) 2006-02-27 2012-08-21 The Regents Of The University Of California Composes oxysterols et voie
CN101164540A (zh) 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
WO2008057468A1 (fr) 2006-11-02 2008-05-15 Curis, Inc. Régulateurs à petites molécules organiques de la prolifération cellulaires
ES2607852T3 (es) 2006-11-21 2017-04-04 Umecrine Ab El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC
EP2170828B1 (fr) 2007-06-20 2012-11-21 Auspex Pharmaceuticals, Inc. N-aryle pyridinones substituees a fonction d'inhibiteurs fibrogenes
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
CA2703497A1 (fr) 2007-11-06 2009-05-14 N.V. Organon Procede de diminution du taux d'hormone chez les etres humains
CA2707663C (fr) 2007-12-03 2017-05-30 The Regents Of The University Of California Oxysterols pour l'activation du signal hedgehog, de l'osteoinduction, de l'anti-adipogenese et du signal wnt
WO2009090063A1 (fr) 2008-01-16 2009-07-23 Jado Technologies Gmbh Dérivés de sapogénine stéroïde, androstane et sapogénine triterpénoïde pour le traitement et la prévention de maladies infectieuses
JP2011520815A (ja) 2008-05-09 2011-07-21 エモリー・ユニバーシテイ 精神神経障害治療のためのｎｍｄａ受容体拮抗薬
WO2010065709A2 (fr) 2008-12-03 2010-06-10 Amin Khan Dérivés d'acide hydroxamique, préparation et utilisations thérapeutiques de ceux-ci
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
US8822462B2 (en) 2009-01-28 2014-09-02 Emory University Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
EP2459581A4 (fr) 2009-07-29 2012-12-26 Univ Chicago Agonistes du récepteur x du foie
WO2011028794A2 (fr) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Traitement de la chorée de huntington avec de la cyclosérine et un agoniste des récepteurs nmda
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (fr) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft Dérivés d'estratriène 14,17-pontés comprenant des bioisostères hétérocycliques pour le noyau phénolique a
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
US20150031655A1 (en) 2011-04-15 2015-01-29 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
EP2714081A4 (fr) 2011-05-27 2015-09-09 Cytocure Llc Méthodes, compositions et trousses pour le traitement du cancer
JP2014521662A (ja) 2011-07-29 2014-08-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド
US20150158903A1 (en) 2011-09-08 2015-06-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
WO2013163455A2 (fr) 2012-04-25 2013-10-31 The Regents Of The University Of California Plate-forme de criblage de médicaments pour le syndrome de rett
US9737522B2 (en) 2012-08-09 2017-08-22 Emory University NMDA receptor modulators and uses related thereto
US20140149272A1 (en) 2012-08-17 2014-05-29 Trueex Group Llc Interoffice bank offered rate financial product and implementation
BR112015014397B1 (pt) 2012-12-18 2021-02-02 Washington University composto, composição farmacêutica e uso de um composto
EP2948152A4 (fr) 2013-01-23 2016-12-14 Sphaera Pharma Private Ltd Nouveaux composés de 11bêta-hydroxy-stéroïdes destinés à être utilisés utilisation dans la biogenèse de mitochondries et les maladies associées avec la dysfonction ou la déplétion mitochondriale
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
LT2968369T (lt) 2013-03-13 2018-12-27 Sage Therapeutics, Inc. Neuroaktyvūs steroidai ir jų panaudojimo būdai
IL286970B2 (en) 2013-03-13 2024-11-01 Sage Therapeutics Inc Neuroactive steroids and methods of use thereof
HRP20200995T1 (hr) * 2013-04-17 2020-11-27 Sage Therapeutics, Inc. 19-nor neuroaktivni steroidi za metode liječenja
EP3049089B1 (fr) 2013-09-25 2019-08-21 Van Andel Research Institute Glucocorticoïdes très puissants
TWI769970B (zh) 2014-02-08 2022-07-11 美商建南德克公司 治療阿茲海默症之方法
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
EP3204011A4 (fr) 2014-10-07 2018-06-20 Sage Therapeutics, Inc. Composés neuroactifs et leurs procédés d'utilisation
MX376833B (es) 2015-07-06 2025-03-07 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
RS62220B1 (sr) 2015-07-06 2021-09-30 Sage Therapeutics Inc Oksisteroli i postupci njihovog korišćenja
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
CN114272249A (zh) 2016-04-01 2022-04-05 萨奇治疗股份有限公司 氧甾醇及其使用方法
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2017292870B2 (en) 2016-07-07 2021-10-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
EP3519422B1 (fr) 2016-09-30 2022-08-31 Sage Therapeutics, Inc. Oxystérols substitués en c7 et ces composés pour l'utilisation en tant que modulateurs nmda
ES2952106T3 (es) 2016-10-18 2023-10-27 Sage Therapeutics Inc Oxisteroles y procedimientos de utilización de los mismos
KR20250054838A (ko) * 2016-10-18 2025-04-23 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
CN110945006A (zh) 2017-06-23 2020-03-31 英特塞普特医药品公司 用于制备胆汁酸衍生物的方法和中间体
SG10202110563YA (en) 2017-11-10 2021-11-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders

Also Published As

Publication number Publication date
AU2024202773A1 (en) 2024-05-16
DK4105223T3 (da) 2025-07-07
IL293231B1 (en) 2025-06-01
IL293231A (en) 2022-07-01
TW201827057A (zh) 2018-08-01
IL320521A (en) 2025-06-01
CN114891056A (zh) 2022-08-12
JP7304444B2 (ja) 2023-07-06
US11111266B2 (en) 2021-09-07
EP4616908A2 (fr) 2025-09-17
US20200123195A1 (en) 2020-04-23
EP3529256B1 (fr) 2023-08-09
JP7821138B2 (ja) 2026-02-26
EP4105223B1 (fr) 2025-04-30
RU2019115112A (ru) 2020-11-24
US20220024968A1 (en) 2022-01-27
KR20190065429A (ko) 2019-06-11
IL266092B2 (en) 2023-08-01
MX2022005160A (es) 2022-06-08
US20250179112A1 (en) 2025-06-05
NZ752728A (en) 2024-08-30
BR112019008069A2 (pt) 2019-09-03
US12180247B2 (en) 2024-12-31
CN110072874A (zh) 2019-07-30
JP2019532079A (ja) 2019-11-07
WO2018075698A1 (fr) 2018-04-26
JP2025184962A (ja) 2025-12-18
EP4616908A3 (fr) 2025-11-26
IL266092B1 (en) 2023-04-01
AU2017345399A1 (en) 2019-05-09
TWI772331B (zh) 2022-08-01
RU2019115112A3 (fr) 2020-12-15
TWI836485B (zh) 2024-03-21
MX2019004679A (es) 2019-10-15
JP2023063535A (ja) 2023-05-09
TW202446399A (zh) 2024-12-01
AU2017345399B2 (en) 2022-02-24
ES2968140T3 (es) 2024-05-08
AU2022200810A1 (en) 2022-02-24
CA3041077A1 (fr) 2018-04-26
KR102521573B1 (ko) 2023-04-14
IL266092A (en) 2019-06-30
JP2022033255A (ja) 2022-02-28
CN110072874B (zh) 2022-08-12
US11613556B2 (en) 2023-03-28
ES3038660T3 (en) 2025-10-14
AU2022200810B2 (en) 2024-02-01
US20230331768A1 (en) 2023-10-19
KR20250054838A (ko) 2025-04-23
CN115322238A (zh) 2022-11-11
KR20230051723A (ko) 2023-04-18
EP4105223A1 (fr) 2022-12-21
EP3529256A1 (fr) 2019-08-28
IL293231B2 (en) 2025-10-01
TW202317138A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3684364A4 (fr) Pyridazinones et leurs procédés d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
FR24C1044I1 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3416634A4 (fr) Agents immunomodulateurs et leurs procédés d'utilisation
EP3510040A4 (fr) Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
EP3298168A4 (fr) Agents réducteurs stabilisés et leurs procédés d'utilisation
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3436030A4 (fr) Récepteurs chimériques et leurs procédés d'utilisation
MA44526A (fr) Oxystérols et leurs méthodes d'utilisation
EP3504213A4 (fr) Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3303634A4 (fr) Variants de cas9 et procédés d'utilisation associés
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
EP3307844A4 (fr) Fluides de forage et leurs procédés d'utilisation
EP3349851A4 (fr) Polypeptides photosensibles et leurs procédés d'utilisation